Summary The Veterans Affairs Vasodilator-Heart Failure Trials (V-HeFT I and II) provided
information about heart failure treated with conventional therapy, and evaluated the long …

Vasodilator drugs have been undergoing evaluation as therapy for heart failure for> 20
years. It has become clear that hemodynamic benefits, short-term improvement in exercise …

Congestive heart failure (CHF) causes disabling symptoms and increases the likelihood of
decreased survival. Diuretics, direct vasodilators, and angiotensin‐converting enzyme …

Abstract Background and Methods. To define better the efficacy of vasodilator therapy in the
treatment of chronic congestive heart failure, we compared the effects of hydralazine and …

Therapy with angiotensin-converting enzyme inhibitors and nonselective vasodilators
(hydralazine and isosorbide dinitrate) has become accepted treatment in patients with …

V-HeFT, the first mortality trial in patients with heart failure, has provided important insights
regarding trial design, including patient selection and efficacy criteria. Planning of V-HeFT II …

We examined existing evidence concerning the relative efficacy of various vasodilator
agents in chronic congestive heart failure. Only randomized placebo-controlled trials with …

PARADIGM-HF trial in the Journal (pages 993–1004) we may be entering a new era of
treatment for heart failure with reduced ejection fraction. To provide a historical perspective …

Congestive heart failure is a major clinical and public health problem affecting between 2
and 3 million people in the United States. Whereas myocardial dysfunction assumes a …

The rationale for the use of vasodilating agents in the treatment of congestive heart failure is
to reverse the systemic vasoconstriction that characterises patients with this disorder, and …